Characteristics of the study population
| Variable | Censored | Death from other cause | Out-of-hospital cardiac arrest | Total |
| Count, no. | 270 825 | 52 735 | 2667 | 326 227 |
| Median age in years (Q1–Q3) | 53.1 [40.2, 64.6) | 78.8 [69.2, 85.4) | 72.5 [62.3, 80.7) | 57.1 [43.0, 70.2) |
| Male sex, no. (%) | 122 412 (45.2) | 23 229 (44.0) | 1650 (61.9) | 147 291 (45.1) |
| Atrial fibrillation | 5073 (1.9) | 6487 (12.3) | 337 (12.6) | 11 897 (3.6) |
| Atrial flutter | 502 (0.2) | 478 (0.9) | 23 (0.9) | 1003 (0.3) |
| Cornell LVH | 7570 (2.8) | 4916 (9.3) | 235 (8.8) | 12 721 (3.9) |
| Sokolow-Lyon LVH | 16 801 (6.2) | 5486 (10.4) | 339 (12.7) | 22 626 (6.9) |
| Left bundle branch block | 2037 (0.8) | 1741 (3.3) | 124 (4.6) | 3902 (1.2) |
| Non-specific intraventricular block | 2526 (0.9) | 889 (1.7) | 109 (4.1) | 3524 (1.1) |
| Right bundle branch block | 4346 (1.6) | 3213 (6.1) | 145 (5.4) | 7704 (2.4) |
| Q-wave | 14 093 (5.2) | 7106 (13.5) | 431 (16.2) | 21 630 (6.6) |
| ST-depression without AF | 4585 (1.7) | 4635 (8.8) | 309 (11.6) | 9529 (2.9) |
| ST-depression with AF | 961 (0.4) | 2228 (4.2) | 117 (4.4) | 3306 (1.0) |
| ST-elevation | 2867 (1.1) | 889 (1.7) | 66 (2.5) | 3822 (1.2) |
| Cardiac disease | ||||
| Cardiomyopathy | 656 (0.2) | 491 (0.9) | 46 (1.7) | 1193 (0.4) |
| Heart failure | 2746 (1.0) | 4830 (9.2) | 339 (12.7) | 7915 (2.4) |
| Ischaemic heart disease (MI not included) | 9884 (3.6) | 6167 (11.7) | 408 (15.3) | 16 459 (5.0) |
| Previous MI | 3285 (1.2) | 2134 (4.0) | 168 (6.3) | 5587 (1.7) |
| AF/atrial flutter | 5339 (2.0) | 5872 (11.1) | 305 (11.4) | 11 516 (3.5) |
| Valvular heart disease | 1034 (0.4) | 1189 (2.3) | 84 (3.1) | 2307 (0.7) |
| Congenital heart disease | 220 (0.1) | 29 (0.1) | 4 (0.1) | 253 (0.1) |
| Other cardiac arrythmia | 3465 (1.3) | 1676 (3.2) | 83 (3.1) | 5224 (1.6) |
| Other cardiac disease | 1148 (0.4) | 538 (1.0) | 33 (1.2) | 1719 (0.5) |
| Other diseases | ||||
| Cerebrovascular disease | 5967 (2.2) | 6005 (11.4) | 251 (9.4) | 12 223 (3.7) |
| Peripheral vascular disease | 2615 (1.0) | 2868 (5.4) | 154 (5.8) | 5637 (1.7) |
| COPD | 5680 (2.1) | 5405 (10.2) | 271 (10.2) | 11 356 (3.5) |
| Malignant disease | 8101 (3.0) | 6206 (11.8) | 183 (6.9) | 14 490 (4.4) |
| Renal disease | 862 (0.3) | 937 (1.8) | 45 (1.7) | 1844 (0.6) |
| Liver disease | 2223 (0.8) | 1000 (1.9) | 48 (1.8) | 3271 (1.0) |
| Medication | ||||
| QTc prolonging medication | 62 801 (23.2) | 19 338 (36.7) | 807 (30.3) | 82 946 (25.4) |
| Glucose lowering medication | 15 344 (5.7) | 5684 (10.8) | 369 (13.8) | 21 397 (6.6) |
| Beta-blockers | 26 436 (9.8) | 10 183 (19.3) | 629 (23.6) | 37 248 (11.4) |
| Diuretics | 41 951 (15.5) | 25 643 (48.6) | 1300 (48.7) | 68 894 (21.1) |
| ACEi/ARB | 48 444 (17.9) | 14 989 (28.4) | 960 (36.0) | 64 393 (19.7) |
| Calcium inhibitors | 27 745 (10.2) | 10 821 (20.5) | 639 (24.0) | 39 205 (12.0) |
All results are reported as the number of patients (%) unless otherwise specified.
ACEi/ARB, ACE inhibitor/angiotensin II receptor blockers; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; LVH, left ventricular hypertrophy; MI, myocardial infarction; Q1–Q3, 1st+3rd quartiles.